DPP-IV Inhibitor Alogliptin and Results of Clinical Trials Showing its Benefits
Continuing with the series of posts on the class of drugs called Dipeptidyl Peptidase-IV inhibitors (DPP-IV), the latest medications being used to treat Type 2 Diabetes Mellitus, we discuss Alogliptin in this blog post. Alogliptin (code named SYR-322) like its sister drugs, Sitagliptin (sold as the brand name Januvia), Vildagliptin (approved in the European Union but awaiting approval in the US) and Saxagliptin, is a DPP-IV inhibitor.
This means that Alogliptin blocks the action of the enzyme Dipeptidyl Peptidase, which normally catalyzes the peptides GLP-1, known to increase insulin secretion and thus reduce blood sugar (the incretin effect). Alogliptin has a high affinity for the DPP-4 enzyme, the strongest in this class of drugs. Alogliptin is being investigated as a medication to treat Type 2 Diabetes Mellitus alone or in combination with drugs like Metformin or Glyburide. The drug is manufactured by Takeda Pharmaceuticals. (Read more details about Alogliptin )
Results from Clinical trials on the Effectiveness of Alogliptin (SYR-322)
1. A 26 week long study with 329 patients who had never been treated for Type 2 Diabetes where given one of a) Alogliptin 12.5 mg, b) Alogliptin 25 mg or c) Placebo.
The groups receiving the Alogliptin had 0.56% point reduction in the levels of HbA1c (a marker for long term blood sugar levels)
2. Another 26 weeks long study with 650 patients who had never been treated for Type 2 Diabetes where given one of a) Alogliptin 25 mg, b) Pioglitazone 30 mg , c) Alogliptin 12.5 mg + Pioglitazone 30 mg or d) Alogliptin 25 mg + Pioglitazone 30 mg. However the combination of Alogliptin + Pioglitazone results in slight increase in body weight.
Similar results, that is decrease in HbA1c have also been obtained when the drug is given in combination with Metformin or Glyburide.
At this time, Alogliptin has shown good ability to reduce blood sugar and has acceptable tolerability and side effects. However, the drug is still undergoing clinical testing as its risk for cardio-vascular side effects are still being evaluated and FDA has asked Takeda to provide additional data (which it expects to by 2012)
Here are some clinical trials of Alogliptin under way currently .